PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Entera Bio Ltd (ENTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

IL0011429839

CUSIP

M40527109

Sector

Healthcare

IPO Date

Jun 28, 2018

Highlights

Market Cap

$82.50M

EPS (TTM)

-$0.26

Total Revenue (TTM)

$99.00K

Gross Profit (TTM)

-$4.00K

EBITDA (TTM)

-$7.21M

Year Range

$1.00 - $3.35

Target Price

$10.00

Short %

0.20%

Short Ratio

0.29

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Entera Bio Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
35.78%
9.31%
ENTX (Entera Bio Ltd)
Benchmark (^GSPC)

Returns By Period

Entera Bio Ltd had a return of 5.66% year-to-date (YTD) and 113.33% in the last 12 months.


ENTX

YTD

5.66%

1M

-4.27%

6M

35.76%

1Y

113.33%

5Y*

-6.92%

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of ENTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20253.30%5.66%
202440.07%63.61%21.45%17.37%14.80%-18.22%-12.50%3.73%13.77%-4.74%-9.39%29.27%253.33%
202325.75%-2.40%29.46%-33.62%2.99%6.36%-5.98%-12.99%5.07%-5.52%3.64%-15.48%-17.81%
2022-18.65%-6.99%34.74%-14.63%-12.24%-38.14%45.86%-30.41%-22.96%-24.75%-13.26%7.54%-74.07%
202135.19%13.70%129.52%-12.07%-3.58%85.14%-14.05%-5.06%-3.48%-9.55%-21.60%-15.72%160.65%
202047.20%-0.32%-34.46%10.78%-15.79%-4.17%-8.15%-24.26%-3.13%-16.13%18.27%-12.20%-49.53%
201931.15%8.75%-0.57%1.72%-21.59%-0.58%-4.66%-20.49%-4.23%-2.41%-7.41%-4.89%-29.84%
20180.32%-14.29%0.00%7.59%-1.89%-6.84%-42.56%-51.43%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 81, ENTX is among the top 19% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ENTX is 8181
Overall Rank
The Sharpe Ratio Rank of ENTX is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ENTX is 8484
Sortino Ratio Rank
The Omega Ratio Rank of ENTX is 7878
Omega Ratio Rank
The Calmar Ratio Rank of ENTX is 8383
Calmar Ratio Rank
The Martin Ratio Rank of ENTX is 7575
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Entera Bio Ltd (ENTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ENTX, currently valued at 1.32, compared to the broader market-2.000.002.001.321.74
The chart of Sortino ratio for ENTX, currently valued at 2.33, compared to the broader market-4.00-2.000.002.004.006.002.332.35
The chart of Omega ratio for ENTX, currently valued at 1.26, compared to the broader market0.501.001.502.001.261.32
The chart of Calmar ratio for ENTX, currently valued at 1.33, compared to the broader market0.002.004.006.001.332.61
The chart of Martin ratio for ENTX, currently valued at 3.56, compared to the broader market0.0010.0020.0030.003.5610.66
ENTX
^GSPC

The current Entera Bio Ltd Sharpe ratio is 1.32. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Entera Bio Ltd with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.001.502.002.503.003.50SeptemberOctoberNovemberDecember2025February
1.32
1.74
ENTX (Entera Bio Ltd)
Benchmark (^GSPC)

Dividends

Dividend History


Entera Bio Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-67.54%
0
ENTX (Entera Bio Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Entera Bio Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Entera Bio Ltd was 92.75%, occurring on Nov 11, 2022. The portfolio has not yet recovered.

The current Entera Bio Ltd drawdown is 67.54%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.75%Mar 15, 2021422Nov 11, 2022
-84.63%Jul 11, 2018582Dec 16, 202058Mar 12, 2021640
-2.11%Jul 5, 20181Jul 5, 20183Jul 10, 20184

Volatility

Volatility Chart

The current Entera Bio Ltd volatility is 19.39%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
19.39%
3.07%
ENTX (Entera Bio Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Entera Bio Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Entera Bio Ltd.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab